Introduction {#Sec1}
============

Allergic asthma is a heterogeneous inflammatory lung disease that affects \~334 million people worldwide^[@CR1],[@CR2]^. The disease is caused by individual genetic factors and is aggravated by environmental insults such as viral infection, irritants, and allergens in dust, animal fur, and pollen^[@CR1]^. In most cases, patients with asthma are prescribed inhaled corticosteroids with or without long-lasting ß agonists, theophyllines, or leukotriene-receptor antagonists, according to their symptoms^[@CR3]^. However, these anti-asthmatic therapies are limited to symptomatic treatment and may incur severe side effects. Furthermore, despite receiving multiple therapies, \~40% of patients with asthma remain symptomatic, and up to 5% have difficult-to-control asthma^[@CR3],[@CR4]^. In this context, many researchers have focused on improving disease control by studying methods to reduce the administration of corticosteroids to patients with severe allergic asthma. Nevertheless, the number of patients with asthma has not fallen much.

House dust mites (HDMs) are the most prevalent triggers of asthma, and \~85% of asthmatics are allergic to HDMs^[@CR5]^. In particular, *Dermatophagoides pteronyssinus* (*Der p*) and *D*. *farina*e (*Der f*) stimulate the production of Th2 pro-inflammatory cytokines, including Interleukin 4 (IL-4) and Interleukin 13 (IL-13)^[@CR5],[@CR6]^. We have reported that phospholipase D1 (PLD1) is a key enzyme in the production of IL-13 in response to *Der f* 2 and have suggested that it is a potential therapeutic target in allergic disorders^[@CR7],[@CR8]^. PLD1 is a membrane-associated enzyme that catalyzes the hydrolysis of phosphatidylcholine to yield the lipid second messenger phosphatidic acid and free polar head group choline^[@CR9]^. However, targeting of PLD1 can incur systemic adverse effects because it is a ubiquitous enzyme involved in membrane trafficking^[@CR10]^, cytoskeletal rearrangement^[@CR11]^, differentiation^[@CR12],[@CR13]^, survival^[@CR14],[@CR15]^, and autophagy^[@CR16]^. Although small-molecule PLD1 inhibitors showed significant therapeutic effects in cancer^[@CR17],[@CR18]^, autoimmunity^[@CR19]^, and kidney disease^[@CR20]^, their use is limited because of side effects, selectivity, and toxicity. We previously reported that PLD1 is specifically inactivated by binding to AP180 (assembly protein, 180 kDa), an important factor in clathrin-mediated endocytosis of synaptic vesicles^[@CR21],[@CR22]^. Moreover, we identified the PLD1-specific binding motif of AP180 and demonstrated that the pentapeptide (TVTSP) in this motif was effective as an anticancer adjuvant^[@CR23]^. Thereafter, based on these reports, we registered two domestic patents^[@CR24],[@CR25]^. However, it is not known whether this peptide has any therapeutic potency in allergic diseases, including asthma.

Efficient delivery of therapeutic biomolecules to target tissues is a challenging problem because they poorly penetrate the cellular membrane. Cell-penetrating peptides (CPPs), small cationic peptides derived from proteins that can cross phospholipid bilayers, offer one possible solution^[@CR26]^. CPPs, as a helpful tool for the intracellular delivery of various molecules, such as peptides, proteins, siRNAs, and therapeutic agents, have been studied in various fields^[@CR27]^. In particular, TAT (trans-activator of transcription) is internalized via clathrin-mediated endocytosis and micropinocytosis and is assumed to be biologically inert^[@CR28]^. It has been used in preclinical models to study pain^[@CR29]^, ischemia^[@CR30]^, cancer^[@CR31]^, and inflammation^[@CR32]^, and there have been over 20 phase I and phase II clinical trials involving more than 2000 patients treated with CPP-fused therapeutics^[@CR33]^. These results imply that CPPs can be used as an efficient drug delivery system.

Here, we aimed to develop a novel agent that suppressed airway inflammation by targeting PLD1 and to assess its in vivo toxicity. We designed TAT-TVTSP, a PLD1-specific inhibitory peptide fused with TAT, as the delivery vehicle. TAT-TVTSP effectively penetrated bronchial epithelial cells and airway tissues and significantly reduced *Der f* 2-induced PLD activation and airway inflammation in vitro as well as in vivo. Furthermore, TAT-TVTSP was found to be relatively safe in single- and repeated-dose toxicity studies of a mouse model. These findings indicate that therapy using a PLD1-inhibitory peptide fused with a CPP delivery system can be an efficient and promising strategy to prevent allergic asthma induced by HDMs.

Materials and methods {#Sec2}
=====================

Cell culture {#Sec3}
------------

BEAS-2B, a human bronchial epithelial cell, was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). BEAS-2B cells were cultured in DMEM/F-12 with 10 % (v/v) heat-inactivated FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin (Wisent INC, St.-Bruno, QC, Canada) at 37 °C in a humidified 5% CO~2~-controlled incubator.

Materials {#Sec4}
---------

The house dust mite allergen *Der f* 2 was provided by the Arthropods of Medical Importance Resource Bank, Yonsei University, College of Medicine (Seoul, Korea), as described previously^[@CR8]^. Peptides were synthesized by CosmoGenetech (Seoul, Korea) and were validated by HPLC and mass spectrometry (data not shown). PLD inhibitors (FIPI and VU0155069) were supplied by Tocris (Oxford, UK).

Determination of PLD activity {#Sec5}
-----------------------------

PLD activity was determined in \[^3^H\]-palmitic acid-labeled cells by measuring the amount of \[^3^H\]-phosphatidylbutanol (PBt) produced by PLD-catalyzed transphosphatidylation in the presence of 1-butanol, as described previously^[@CR34]^. BEAS-2B cells were labeled with 2 µCi/ml \[^3^H\]-palmitic acid (DuPont-New England Nuclear, Boston, MA, USA) in serum-free medium for 18 h. They were then pretreated with 0.3% (v/v) 1-butanol for 15 min before stimulation with *Der f* 2. Cells were pre-incubated with TAT, TAT-TVTSP, FIPI, or VU0155069 for 2 h after labeling with \[^3^H\]-palmitic acid. After treatment with *Der f* 2 for 30 min, the cells were washed with ice-cold PBS and suspended in ice-cold methanol. Lipids were extracted, and PBt was separated by thin layer chromatography using an ethylacetate/isooctane/acetic acid/water (26:4:6:20, v/v) solvent system. Authentic PBt bands (*R*~f~ = 0.76) were identified with 0.002% (w/v) primulin dissolved in 80% (v/v) acetone, scraped, and counted in a liquid scintillation counter (PerkinElmer, Norwalk, CT, USA).

Real-time PCR and reverse transcription (RT)-PCR {#Sec6}
------------------------------------------------

Total cellular RNA was isolated using RNAiso Plus (Takara Bio, Ohtsu, Japan). Next, 2 µg of isolated total RNA was mixed with the Reverse Transcription Master premix kit (Elpis Bio, Daejeon, Korea), and the mixture was incubated for 60 min at 37 °C. The transcribed products were mixed with each primer set and Go*Taq* DNA polymerase (Promega, Madison, WI, USA) and were amplified in a PCR machine (Takara Bio). The primer sequences were as follows: *IL-13* sense (5′-GAGTGTGTTTGTCACCGTTG-3′) and antisense (5′-TACTCGTTGGTCGAGAGCTG-3′); *GAPDH* sense (5′-CATGAGAAGTATGACAACAGCCT-3′) and antisense (5′-AGTCCTTCCACGATACCAAAGT-3′). The PCR conditions for *IL-13* and *GAPDH* were as follows: denaturation at 95 °C for 30 s, annealing at 56 °C for 30 s, and extension at 72 °C for 40 s (35 cycles and 26 cycles). PCR products were analyzed on a 1.5% agarose gel. For real-time PCR, an aliquot of 1 µl of cDNA was amplified in duplicate in a final volume of 20 µl using the SensiFAST™ SYBR® NO-ROX Kit (Bioline, London, UK). The thermocycling conditions were 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 56 °C for 1 min. The primer sequences for real-time PCR were the same as those for RT-PCR.

ELISA {#Sec7}
-----

Cell supernatants were collected after *Der f* 2 treatment, and the concentrations of IL-13 were measured using a commercial ELISA kit (Bender Medsystems, Vienna, Austria) following the manufacturer's instructions. The concentrations of samples were determined from a standard curve ranging from 3.13 to 200 pg/ml. For mouse experiments, lung tissues were homogenized in 20 ml/g tissue protein extraction reagent (ThermoFisher, Rockford, IL, USA) using a tissue homogenizer (Biospec Products, Bartlesville, OK, USA). Homogenates were incubated at 4 °C for 30 min and centrifuged at 1000×*g* for 10 min. The supernatants were collected and passed through a 0.45-micron filter (Gelman Sciences, Ann Arbor, MI, USA) for the measurement of cytokine levels.

Cell viability {#Sec8}
--------------

Cells were incubated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Duchefa, Haarlem, Netherlands) solution at 37 °C for 4 h. Dark brown formazan crystals formed after the reduction of tetrazolium by the mitochondria of living cells dissolved in DMSO, and the optical densities were read at 570 nm with a microplate reader (BioRad, Hercules, CA, USA).

Measurement of delivery efficiency {#Sec9}
----------------------------------

Cells were plated onto coverslips in 24-well plates, and TAT-TVTSP-FAM (Supplementary Figure [2](#MOESM1){ref-type="media"}) was added for the indicated times. After removal of the medium, the cells were fixed with 4% PFA (Sigma-Aldrich, St. Louis, MO, USA) for 15 min. The medium was replaced by 0.1% BSA in PBS, and the cells were mounted on slides with Vectashield (DAKO, Glostrup, Denmark). FAM signals were photographed using a fluorescence microscope (Leica Microsystems, Wetzlar, Germany). The tissue permeability of TAT-TVTSP was also examined in a mouse model. Five-week-old female mice habituated for 1 week were intranasally administered TAT-TVTSP-FAM or saline. The tracheas and bronchioles were excised 2 h later and were immediately frozen in optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA, USA) and sectioned at a thickness of 10 µm. The sections were fixed with 4% PFA for 15 min, washed with 0.1% BSA in PBS, and mounted with Vectashield. Intracellular fluorescence signals were observed using a fluorescence microscope.

Animals {#Sec10}
-------

Female 6-week-old BALB/c mice (Orient, Gyeonggi-do, Korea) were used to generate the mouse model of allergic airway inflammation. For the in vivo toxicity studies, male and female 5-week-old ICR mice (Koathech, Gyeonggi-do, Korea) were used. They were maintained under specific pathogen-free conditions, fulfilling the standards of facilities approved by the American Association for the Accreditation of Laboratory Animal Care. All animal experiments were performed in accordance with the Korean Food and Drug Administration guidelines.

Mouse model of allergic airway inflammation {#Sec11}
-------------------------------------------

The protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Hanyang Laboratory Animal Research Center (2015-0197A). The mice were assigned to the saline, *Der f* 2, *Der f* 2 + TAT or *Der f* 2 + TAT-TVTSP groups. As shown in Fig. [2a](#Fig2){ref-type="fig"}, TAT or TAT-TVTSP was administered intranasally 2 h prior to the intranasal injection of *Der f* 2 (1.2 mg/kg), and this was repeated 7 times over 2 weeks.

Histology {#Sec12}
---------

Lung tissues were fixed in 10% formalin, embedded in paraffin, and sectioned. Sections were counterstained with H&E or PAS for histological examination using standard techniques. After staining, the slides were rinsed in distilled water, mounted with Vectashield, and photographed using an optical microscope (Olympus, Tokyo, Japan).

AHR measurement {#Sec13}
---------------

Airway hyperresponsiveness (AHR) was measured using a whole-body plethysmographic chamber (OCP-3000; Allmedicus, Gyeonggi-do, Korea). The mice were exposed to the indicated concentrations of methacholine (Sigma-Aldrich) using an ultrasonic nebulizer (Omron Healthcare, Kyoto, Japan). After placing the mouse in the chamber, airway responsiveness was measured by evaluating enhanced pause (Penh). Penh, as an index of airway hyperresponsiveness, was calculated as previously described^[@CR35]^.

BALF assay {#Sec14}
----------

Bronchoalveolar lavage fluid (BALF) was obtained as previously described^[@CR36]^. Lungs were lavaged with 1 ml of Hank's balanced salt solution via a tracheostomy tube. The total cell numbers were counted using a hemocytometer (Sigma-Aldrich). BALF was then centrifuged at 1500×*g* for 3 min at 4 °C, and smears of BAL cells were prepared by cytocentrifugation (Cytospin3; Thermo, Billerica, MA, USA) at 1000 rpm for 3 min. BAL cells were stained using a Hemacolor Staining Kit (Merck, Darmstadt, Germany), counted and classified as neutrophils, eosinophils, lymphocytes, or macrophages.

Single-dose toxicity study {#Sec15}
--------------------------

Protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Hanyang Laboratory Animal Research Center (2016-0038A). Forty animals aged 5 weeks were randomly assigned to four different dose groups (Supplementary Table [1](#MOESM2){ref-type="media"}), and each concentration of TAT-TVTSP was injected intranasally. Changes in the clinical signs, body weight, and blood analysis indices were evaluated. All the animals were euthanized on day 14, except for four mice that had to be sacrificed earlier. Mortality was recorded, and tissues from the heart, kidney, liver, stomach, spleen, lung, intestine, and brain were collected for immediate necropsy. After fixation, organs sampled for histology were stained with H&E according to the standard procedures. In addition, blood samples were freshly drawn from each heart and were analyzed at the Korea Conformity Laboratories (Incheon, Korea). The following standard hematology markers were analyzed: red blood cell count, hemoglobin, hematocrit, mean corpuscle volume, mean corpuscle hemoglobin concentration, platelet count, and white blood cell count. Additionally, blood samples were centrifuged twice at 3000 rpm for 10 min to separate sera. Liver function was evaluated from the serum levels of total bilirubin (T-BIL) and alkaline phosphatase (ALP). Albumin (ALB) was assayed as a measure of tissue damage or inflammation. Gamma glutamyl transferase (GGT) and total protein (TP) were also quantified. These parameters were determined using a Biochemical Autoanalyzer (Type 7170; Hitachi, Japan).

Repeated-dose toxicity study {#Sec16}
----------------------------

Protocols were reviewed and approved by the Institution Animal Care and Use Committee of the Hanyang Laboratory Animal Research Center (2016-0038A). Forty animals (20 males and 20 females) were randomly allocated to four different dose groups (Supplementary Table [1](#MOESM2){ref-type="media"}). TAT-TVTSP (or saline) was administered intranasally every day for 4 weeks. Other procedures were similar to those in the "Single-dose toxicity study" section.

Statistics {#Sec17}
----------

Statistical analysis for a complex sampling design was performed using SPSS software, version 18.0 (SPSS Inc., Chicago, IL, USA). The data are expressed as the means ± SD of at least three independent experiments; *P* \< 0.05 was considered statistically significant. Comparisons between groups were made using unpaired Student's *t*-tests, and multi-group comparisons of means were carried out by one-way repeated-measures analysis of variance (ANOVA).

Results {#Sec18}
=======

TAT-TVTSP is efficiently delivered into BEAS-2B cells and reduces *Der f* 2-induced PLD activation and IL-13 production {#Sec19}
-----------------------------------------------------------------------------------------------------------------------

We investigated whether a peptide in the PLD1-specific binding motif of AP180 was applicable as an inhibitor of airway inflammation induced by the house dust mite allergen *Der f* 2. As shown in Fig. [1a](#Fig1){ref-type="fig"}, we designed a PLD1-inhibitory peptide (TVTSP) coupled with TAT as a delivery vehicle. To verify whether this peptide (TAT-TVTSP) regulated PLD activity, human bronchial epithelial cells (BEAS-2B) were exposed to *Der f* 2 (20 µg/ml) for 30 min after pretreatment with TAT-TVTSP (10 or 20 µM) or TAT (10 µM) for 2 h. *Der f* 2-induced PLD activation was repressed by TAT-TVTSP in a dose-dependent manner (Fig. [1b](#Fig1){ref-type="fig"}). Moreover, as shown in Supplementary Figure [1](#MOESM1){ref-type="media"}, TAT-TVTSP efficiently decreased *Der f* 2-induced PLD activation compared with excess treatment (50 µM) or Lipofectamine-mediated transfection of TVTSP, indicating that TAT powerfully acted as a transcellular delivery cargo. To further examine the efficiency of delivery of TAT-TVTSP, we labeled its C-terminus with the fluorescent dye FAM (Supplementary Figure [2](#MOESM1){ref-type="media"}) and measured the intracellular fluorescence over a time course. Green fluorescence was detected in almost all cells 1 h after exposure to TAT-TVTSP-FAM, and the signals were strongest after 2 h (Fig. [1c](#Fig1){ref-type="fig"}). Next, we found that *Der f* 2-induced IL-13 mRNA expression was significantly reduced by TAT-TVTSP (Fig. [1d, e](#Fig1){ref-type="fig"}), and the same was true for IL-13 production itself (Fig. [1f](#Fig1){ref-type="fig"}). Moreover, exposure to TAT-TVTSP had no effect on cell viability (Fig. [1g](#Fig1){ref-type="fig"}). Interestingly, the inhibitory effect of TAT-TVTSP on IL-13 expression was similar to that of other PLD inhibitors, FIPI and VU0155069 (Supplementary Figure [3](#MOESM1){ref-type="media"}). In summary, TAT-TVTSP was efficiently delivered into bronchial epithelial cells and reduced *Der f* 2-induced PLD activation and IL-13 production without any cytotoxicity.Fig. 1TAT-TVTSP effectively reduces *Der f* 2-induced PLD activation and IL-13 production in BEAS-2B cells.**a** PLD1-specific inhibitory peptide (TVTSP) was fused with the cell-penetrating peptide delivery system (TAT). **b** BEAS-2B cells were labeled with 2 µCi/ml \[^3^H\]-palmitic acid and then pretreated with TAT or TAT-TVTSP at the indicated concentrations for 2 h, followed by stimulation with 20 µg/ml *Der f* 2 for 30 min. PLD activities were determined by estimating \[^3^H\]-PBt in the presence of 1-butanol. The results are expressed as the means ± SD of three independent experiments. \*\**P* \< 0.01 compared with TAT-TVTSP (10 µM) + *Der f* 2/TAT + *Der f* 2 or TAT-TVTSP (20 µM) + *Der f* 2/TAT + *Der f* 2. **c** BEAS-2B cells were treated with TAT-TVTSP-FAM and examined over time. FAM fluorescent signals were examined with a fluorescence microscope. Scale bar, 20 µm. **d**, **e** Total RNA was isolated using Trizol reagent, and the mRNA levels of *IL-13* and *GAPDH* were determined by RT-PCR (**d**) and real-time RT-PCR (**e**). The results are expressed as the means ± SD of three independent experiments. \**P* \< 0.05 compared with TAT-TVTSP (10 µM) + *Der f* 2/TAT + *Der f* 2. \*\**P* *\<* 0.01 compared with TAT-TVTSP (20 µM) + *Der f* 2/TAT + *Der f* 2. **f** Cell supernatants were collected after *Der f* 2 treatment for 30 min, and the concentrations of IL-13 were measured with ELISA. The results are expressed as the means ± SD of three independent experiments. \**P* *\<* 0.05 compared with TAT-TVTSP (10 µM) + *Der f* 2/TAT + *Der f* 2 or TAT-TVTSP (20 µM) + *Der f* 2/TAT + *Der f* 2. **g** An MTT assay was performed after 30 min of treatment with *Der f* 2. The results are expressed as the means ± SD of three independent experiments. All differences were assessed by Student's *t*-test

Intranasally administered TAT-TVTSP is efficiently transferred into airway tissues and blocks airway inflammation in a mouse model of *Der f* 2-induced acute allergic asthma {#Sec20}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To confirm whether TAT-TVTSP was also effective in vivo, we made a HDM-induced airway inflammation mouse model of acute allergic asthma^[@CR8]^. Female 6-week-old mice were intranasally injected with TAT or TAT-TVTSP (10 mg/kg) for 2 h prior to the administration of *Der f* 2 (1.2 mg/kg), and this was repeated 7 times over 2 weeks (Fig. [2a](#Fig2){ref-type="fig"}). We first assessed the delivery efficiency of TAT-TVTSP to target tissues by analyzing in vivo FAM fluorescence 2 h after intranasal injection of TAT-TVTSP-FAM. Considerable accumulation of green fluorescence was observed in both bronchioles and tracheas (Fig. [2b](#Fig2){ref-type="fig"}). Next, we investigated whether TAT-TVTSP affected airway inflammation in vivo. Lung histology was examined to evaluate the extent of inflammation, epithelial hyperplasia, and mucus secretion by goblet cells in airway tissues. As shown in Fig. [2c](#Fig2){ref-type="fig"}, after the injection of TAT (or saline), the intranasal administration of *Der f* 2 stimulated the infiltration of peribronchial inflammatory cells, resulting in thickening of the airway tissues as well as increased secretion of mucus around the bronchial airways. Remarkably, these effects were prevented by intranasal challenge with TAT-TVTSP. Moreover, compared with pretreatment with TAT (or saline), TAT-TVTSP almost completely blocked *Der f* 2-induced IL-13 production (Fig. [2d](#Fig2){ref-type="fig"}). We also evaluated airway hyperresponsiveness (AHR) by analyzing lung resistance to methacholine (Fig. [2e](#Fig2){ref-type="fig"}). Intranasal administration of TAT-TVTSP substantially attenuated *Der f 2*-developed AHR to nebulized methacholine, implying that it blocked allergic inflammation and AHR. The number of immune cells in BALFs was also significantly decreased by TAT-TVTSP (Fig. [2f](#Fig2){ref-type="fig"}). Taken together, we conclude that targeting of PLD1 with TAT-TVTSP has powerful anti-inflammatory effects on the *Der f* 2-induced allergic airway inflammation model and may be an effective therapeutic for allergic diseases, including asthma.Fig. 2Intranasally administered TAT-TVTSP efficiently blocks airway inflammation in a *Der f* 2-induced acute allergic asthma model.**a** Schedule for the allergic airway inflammation model. **b** Saline or TAT-TVTSP-FAM (10 mg/kg) was intranasally administered in *Der f* 2-induced allergic asthma mouse models. After 2 h, tracheas and bronchioles were prepared for fluorescence microscopy. Scale bar, 50 µm. **c** Lung tissues were sectioned and stained with hematoxylin and eosin (H&E) and periodic acid Schiff (PAS) for histological examination. Scale bar, 100 µm. **d** IL-13 levels in homogenates of the right lung of each mouse were measured by ELISA. The results are expressed as the means ± SD of 15 mice in each group. \*\*\**P* \< 0.001 compared with TAT-TVTSP + *Der f* 2/TAT + *Der f* 2. **e** The Penh value was determined by airway resistance to methacholine. The results are the means ± SD of 15 mice in each group. \**P* \< 0.05 compared with TAT-TVTSP + *Der f* 2/TAT + *Der f* 2 at 12.5 mg/kg or at 25 mg/kg methacholine. \*\**P* \< 0.01 compared with TAT-TVTSP + *Der f* 2/TAT + *Der f* 2 at 50 mg/kg methacholine. **f** Numbers of immune cells in BAL fluid. The data are presented as the means ± SD of 15 mice in each group. \**P* \< 0.05 compared with TAT-TVTSP + *Der f* 2/TAT + *Der f* 2 in total cells or in macrophages. \*\**P* \< 0.01 compared with TAT-TVTSP + *Der f* 2/TAT + *Der f* 2 in eosinophils, neutrophils, or lymphocytes. All differences were assessed by Student's *t*-test

Single-dose toxicity study {#Sec21}
--------------------------

We next investigated whether TAT-TVTSP is clinically applicable as a novel anti-asthmatic agent. In the dose-probing pilot study for the toxicity test, 3 mice in the 250 mg/kg group, 5 in the 500 mg/kg group, and 7 in the 1000 mg/kg group died, indicating that the median lethal dose (LD~50~) of TAT-TVTSP was 453.8 mg/kg, when calculated by the Behrens--Kärber method (Supplementary Figure [4](#MOESM1){ref-type="media"} and Fig. [3a](#Fig3){ref-type="fig"}). In addition, 6 mice (3 male and 3 female animals) were challenged with TAT (1000 mg/kg). Two of these (1 male and 1 female) died on day 0. At full necropsy, we found that they had suffocated to death, indicating that intranasal administration caused serious stress. However, the 4 remaining mice showed no any abnormal behavior, and all survived to day 14, implying that TAT is not harmful per se (data not shown).Fig. 3Single-dose toxicity study.**a** Preliminary study for dose selection. **b** Schedule for the single-dose toxicity test. **c** After 14 days, fixed organ samples were dehydrated, paraffinized, and embedded. Sections of 4 µm were stained with H&E and examined by microscopy. Scale bar, 100 µm

Based on this pilot study, a single-dose toxicity study was conducted (Fig. [3b](#Fig3){ref-type="fig"}). At 14 days after exposure, there was less body-weight gain in the TAT-TVTSP-treated groups than in the control group (Supplementary Table [2](#MOESM2){ref-type="media"}). In the low-dose groups, 2 of the 5 female mice had several symptoms such as loss of appetite, no stool, crouching and lacrimation, while the 5 males displayed no abnormal behavior, and all survived. Of two females in this group, one showed symptoms, including alopecia, crouching, edema, and gasping behavior on day 4 and was dead by day 6. Another mouse also had the same symptoms on days 8--11 and died on day 12. In the medium-dose groups, none of the animals had abnormal behavior, and all survived to day 14. In the high-dose groups, 5 (2 male and 3 female) of the 10 mice showed appetite loss and gasping on day 1. Two of them (1 male and 1 female) had serious symptoms, including lacrimation, edema, and gasping; the female died on day 5, and the male died on day 13 (Supplementary Table [3](#MOESM2){ref-type="media"}). Next, blood samples obtained from each mouse were analyzed in detail for serum chemistry and hematology parameters. As shown in Table [1](#Tab1){ref-type="table"}, the serum levels of measured factors were within normal ranges and showed no significant difference. Moreover, the hematological parameters did not change significantly, although the platelet (PLT) levels appeared to rise slightly in female mice, and white blood cell (WBC) and eosinophil (EOS) levels tended to fall with increasing dose (Table [2](#Tab2){ref-type="table"}). Finally, histopathological analysis was conducted by microscopic observation of each tissue in detail. As shown in Fig. [3c](#Fig3){ref-type="fig"}, the lungs, as well as other observed organs, did not undergo any change in appearance and micro-morphology in any of the TAT-TVTSP groups.Table 1Biochemical analysis of sera of male and female mice in the single dose toxicity testTest itemMaleFemaleControlLowMediumHighControlLowMediumHigh0 mg/kg100 mg/kg200 mg/kg500 mg/kg0 mg/kg100 mg/kg200 mg/kg500 mg/kgALB (IU/l)1.78 ± 0.021.80 ± 0.031.78 ± 0.061.70 ± 0.061.32 ± 0.161.57 ± 0.231.43 ± 0.011.35 ± 0.09ALP (IU/l)262.00 ± 56.45221.40 ± 22.83233.20 ± 24.95249.50 ± 12.99229.00 ± 31.95307.00 ± 43.02275.00 ± 23.23258.00 ± 31.65GGT (IU/l)0.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.00TP (IU/l)5.38 ± 0.045.38 ± 0.095.30 ± 0.25.00 ± 0.24.00 ± 0.494.77 ± 0.744.25 ± 0.093.80 ± 0.30T-BIL (IU/l)0.10 ± 0.020.09 ± 0.010.11 ± 0.020.11 ± 0.020.01 ± 0.010.06 ± 0.060.03 ± 0.010.01 ± 0.01Data are expressed as means ± SD (*n* = 5 per each group). Differences were assessed by one-way ANOVA*ALB* albumin, *ALP* alanine aminotransferase, *GGT* gamma (γ)-glutamyl transferase, *TP* total protein, *T-BIL* total bilirubinTable 2Hematological analysis for male and female mice in single dose toxicity studyTest itemMaleFemaleControlLowMediumHighControlLowMediumHigh0 mg/kg100 mg/kg200 mg/kg500 mg/kg0 mg/kg100 mg/kg200 mg/kg500 mg/kgWBC (×10^3^ cell/μl)5.55 ± 3.763.34 ± 1.323.70 ± 1.533.69 ± 1.204.25 ± 1.392.83 ± 0.523.37 ± 0.982.18 ± 1.20RBC (×10^3^ cell/μl)9.25 ± 0.219.35 ± 0.739.19 ± 0.279.10 ± 0.587.95 ± 0.838.36 ± 0.238.27 ± 0.477.84 ± 0.80HGB (g/l)153.20 ± 0.03150.00 ± 0.06149.20 ± 0.04145.50 ± 0.07134.00 ± 0.13137.00 ± 0.01137.30 ± 0.05124.80 ± 0.14HCT (%)50.32 ± 1.1949.86 ± 3.0649.16 ± 0.9348.18 ± 1.8143.45 ± 3.3245.10 ± 0.1443.93 ± 2.2040.30 ± 4.50MCV (fl)54.45 ± 0.8853.36 ± 1.6353.48 ± 1.2753.08 ± 1.6454.75 ± 1.4954.15 ± 1.6353.15 ± 1.0351.4 ± 0.77MCH (pg)16.62 ± 0.3116.04 ± 0.6316.24 ± 0.5215.98 ± 0.3916.85 ± 0.0716.4 ± 0.2816.6 ± 0.6215.9 ± 0.54MCHC (g/l)304.60 ± 0.43300.60 ± 1.02303.80 ± 0.61301.50 ± 0.42307.50 ± 0.64302.50 ± 0.35312.30 ± 0.88309.50 ± 0.87RDW (%)11.38 ± 0.5411.56 ± 0.3011.30 ± 0.5111.10 ± 0.4712.20 ± 0.1012.20 ± 0.4212.08 ± 0.4512.18 ± 0.55PLT (×10^3^ cell/μl)1140 ± 162.701402 ± 268.601391 ± 307.201588 ± 174.60788 ± 67.88788 ± 135.80769 ± 266.30619.5 ± 378.10MPV (fl)4.98 ± 0.254.74 ± 0.354.66 ± 0.374.48 ± 0.135.60 ± 0.706.25 ± 0.505.65 ± 0.496.53 ± 1.59NEUT (%)16.36 ± 4.7023.02 ± 6.0721.6 ± 6.9718.4 ± 5.4717.05 ± 3.6112.75 ± 1.4910.50 ± 2.8020.20 ± 8.69LYM (%)72.88 ± 10.1567.94 ± 6.4569.28 ± 10.3074.48 ± 6.1766.80 ± 4.6756.25 ± 3.7572.30 ± 10.5256.03 ± 8.27MONO (%)0.84 ± 0.380.80 ± 0.220.82 ± 0.360.68 ± 0.240.70 ± 0.140.80 ± 0.280.43 ± 0.251.10 ± 0.42EOS (%)8.76 ± 5.897.34 ± 2.837.64 ± 5.565.33 ± 3.3214.2 ± 8.4929.05 ± 5.4515.88 ± 12.2217.65 ± 7.78LUC (%)0.88 ± 0.770.74 ± 0.290.62 ± 0.260.88 ± 0.210.80 ± 0.140.75 ± 0.210.65 ± 0.544.85 ± 7.80BASO (%)0.28 ± 0.380.20 ± 0.190.24 ± 0.180.28 ± 0.310.45 ± 0.210.40 ± 0.140.25 ± 0.310.43 ± 0.43NEUT (×10^3^ cell/μl)0.77 ± 0.200.72 ± 0.260.72 ± 0.130.67 ± 0.270.75 ± 0.400.37 ± 0.110.35 ± 0.100.44 ± 0.28LYM (×10^3^ cell/μl)4.30 ± 3.562.32 ± 1.042.68 ± 1.492.79 ± 1.072.87 ± 1.131.61 ± 0.402.50 ± 0.961.21 ± 0.74MONO (×10^3^ cell/μl)0.04 ± 0.030.03 ± 0.010.03 ± 0.020.03 ± 0.010.03 ± 0.010.03 ± 0.010.02 ± 0.010.02 ± 0.01EOS (×10^3^ cell/μl)0.36 ± 0.180.24 ± 0.150.23 ± 0.080.17 ± 0.030.55 ± 0.160.81 ± 0.000.48 ± 0.260.41 ± 0.31LUC (×10^3^ cell/μl)0.07 ± 0.110.03 ± 0.010.02 ± 0.020.04 ± 0.010.03 ± 0.000.02 ± 0.000.02 ± 0.020.07 ± 0.11BASO (×10^3^ cell/μl)0.01 ± 0.010.01 ± 0.010.01 ± 0.000.01 ± 0.000.02 ± 0.010.02 ± 0.010.01 ± 0.010.01 ± 0.01Retic (%)3.28 ± 0.832.30 ± 0.512.63 ± 0.512.54 ± 0.433.62 ± 2.522.17 ± 0.333.19 ± 0.653.02 ± 0.63Data are expressed as means ± SD (*n* = 5 per each group). Differences were assessed by one-way ANOVA*WBC* white blood cell, *RBC* red blood cell, *HGB* hemoglobin, *HCT* hematocrit, *MCV* mean corpuscular volume, *MCH* mean corpuscular hemoglobin, *MCHC* mean corpuscular hemoglobin concentration, *RDW* red blood cell distribution width, *PLT* platelet, *MPV* mean platelet volume, *NEUT* neutrophil, *LYM* lymphocyte, *MONO* monocyte, *EOS* eosinophil, *LUC* large unstained cell, *BASO* basophil, *Retic* reticulocyte

Repeated-dose toxicity study {#Sec22}
----------------------------

Based on the single-dose toxicology study and examination of in vivo airway inflammation, we investigated the toxicity of repeated intranasal administration of TAT-TVTSP (Fig. [4a](#Fig4){ref-type="fig"}). All the TAT-TVTSP-treated female groups showed a tendency to gain a little less weight than the control group, whereas all the male groups gained weight similar to the saline group (Supplementary Table [4](#MOESM2){ref-type="media"}). None of the animals showed any clinical manifestations, and all survived to day 28 (Supplementary Table [5](#MOESM2){ref-type="media"}). Moreover, the weights of the liver, lung, spleen, kidney, stomach, and heart were not affected in any of the TAT-TVTSP-treated groups (Fig. [4b](#Fig4){ref-type="fig"} and Supplementary Table [6](#MOESM2){ref-type="media"}). However, the brain weight in the high-dose group was significantly reduced compared with that in the control group (Fig. [4b](#Fig4){ref-type="fig"}). Intranasal injection is frequently used for the delivery of drugs into brain tissues, and PLD1 was previously reported as an important mediator of neurogenesis in brain tissues such as the hippocampus and cortex^[@CR12],[@CR37]^. Therefore, it might be anticipated that repeated intranasal injection of TAT-TVTSP would have some effect on brain development by suppressing PLD1. Finally, histological analysis was conducted by microscopic observation of each tissue, and no organs were affected in the TAT-TVTSP-treated groups (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 4Repeated-dose toxicity study.**a** Schedule for repeated-dose toxicity test of TAT-TVTSP. **b** The organs were weighed, and the values were expressed as the organ weight/body weight and presented as the means ± SD of 10 mice per group. Differences were assessed by one-way ANOVA. \**P* \< 0.05 compared with the brain weight of the untreated control. **c** Fixed organ samples were dehydrated, paraffinized, and embedded. Sections of 4 µm were stained with H&E and observed under a microscope. Scale bar, 100 µm

Discussion {#Sec23}
==========

Asthma is a chronic lung disease characterized by airway inflammation, airflow obstruction, and airway hyperresponsiveness^[@CR1]^. Allergic diseases, including asthma, are generally caused by individual genetic factors and are aggravated by environmental insults^[@CR1]^. House dust mites are the major inhalant allergens of chronic allergic diseases, including childhood asthma^[@CR5],[@CR38]^. HDMs induce airway inflammation by stimulating the production of Th2 pro-inflammatory cytokines^[@CR6],[@CR39]^. We previously demonstrated that PLD1 is activated in T lymphocytes of *Dermatophagoides farinae*-specific allergic patients^[@CR40]^. Furthermore, we showed that *Der f* 2 stimulated IL-13 production by activating PLD1 in human bronchial epithelial cells^[@CR7],[@CR8]^, indicating that targeting PLD1 might suppress airway inflammation by inhibiting IL-13 expression. However, targeting of PLD1 can result in systemic adverse effects because PLD1 is involved in various biological processes. Therefore, topical targeting of PLD1 is extremely important to avoid the side effects.

PLD1 is an important enzyme responsible for the production of the lipid second messenger phosphatidic acid by catalyzing the hydrolysis of phospholipids^[@CR9]^. Primary alcohols (for example, *n*-butanol) act as competitive nucleophiles to water, resulting in a transphosphatidylation to produce phosphatidylalcohols (for example, phosphatidylbutanol), instead of phosphatidic acid^[@CR18]^. Based on this principle, *n*-butanol has been used as a PLD inhibitor in various studies^[@CR41]^, but it has several problems, such as indirect targeting, intracellular complementary systems, low efficiency, and side effects. Consequently, new specific PLD inhibitors need to be developed^[@CR18]^. Several small-molecule PLD inhibitors have been shown to be effective in various diseases, but they also have limitations in terms of selectivity, side effects, and toxicity. In these circumstances, we recently developed a small peptide consisting of five amino acids that binds to and inactivates PLD1^[@CR23]^. However, the peptide may be quickly degraded by intracellular functions, including peptidase effects or autophagy^[@CR42]^, and the delivery into cells or tissues can be limited by the low-penetrating efficiency in crossing the cellular membrane. These issues evoked the necessity for the appropriate topical targeting of PLD1 and application of efficient drug delivery systems. Therefore, we considered the utilization of a CPP as a delivery cargo and constructed TAT-TVTSP, a PLD1-specific inhibitory peptide fused with TAT. As expected, TAT-TVTSP was efficiently transferred into airway tissues and strongly suppressed *Der f* 2-induced airway inflammation indices, indicating that it has powerful possibilities as an anti-asthma agent.

Although TAT was first regarded as a biologically inert vehicle, recent studies have reported that it can affect various cellular processes^[@CR43]^. In HeLa cells, a TAT-derived peptide inhibited tumor necrosis factor-mediated signal transduction^[@CR44]^, and a microarray study revealed altered gene expression patterns after the application of HIV-1 TAT^[@CR45]^. Moreover, in human lung epithelial cells, TAT modulated inflammatory responses by inhibiting the production of multiple cytokines and induced apoptosis^[@CR46]^. However, despite these reports, TAT appeared to only act as a delivery vehicle in the present study. It was not cytotoxic, and the previously reported *Der f* 2 effects, such as PLD activation and IL-13 upregulation in vitro, as well as bronchial inflammation stimulation in vivo, were faithfully reproduced (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).

Toxicological analysis of a pro-drug is critical in evaluating its clinical potential. The general toxicity of drugs needs to be appraised through single- and repeated-dose experiments because toxicants may induce acute and chronic effects depending on the dose and duration of drug exposure. Therefore, we investigated the safety of TAT-TVTSP as a therapeutic agent through single- and repeated-dose toxicity test in a mouse model. The median lethal dose (LD~50~) of TAT-TVTSP was calculated to be \~450 mg/kg. In the single-dose toxicology study, TAT-TVTSP induced acute toxicity, including the loss of body weight and several clinical signs (crouching and lacrimation). Nevertheless, we observed no statistically significant effects on hematology, serum biochemistry, and histopathology. In the repeated-dose toxicology study, TAT-TVTSP also did not display strong toxicity. However, the brain weight was significantly reduced in the high-dose group, suggesting that repeated intranasal injection of TAT-TVTSP might cause the suppression of brain functions via unexpected targeting. Further studies of the pharmacokinetics of TAT-TVTSP are required to address its unexpected brain targeting. Nonetheless, we may conclude that TAT-TVTSP as a novel and effective PLD1 inhibitor suppresses HDM-induced airway inflammation in vitro as well as in vivo. Furthermore, topical application of TAT-TVTSP as a novel inhaled anti-asthmatic drug is expected to reduce the adverse effects that can be caused by the systemic inhibition of PLD.
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